Feasibility of continued treatment with dupilumab in patients with type 2 inflammatory disease who developed eosinophilic pneumonia: 3 case reports

Several reports have described dupilumab‐induced eosinophilic pneumonia (EP) after treatment with dupilumab in patients with type 2 inflammatory disease. Other reports have suggested the efficacy of dupilumab for chronic EP (CEP). Whether dupilumab can be continued in patients with type 2 inflammato...

Full description

Saved in:
Bibliographic Details
Published in:Respirology case reports 2024-06, Vol.12 (6), p.e01412-n/a
Main Authors: Hamakawa, Masamitsu, Tanaka, Ayaka, Tokioka, Fumiaki, Ishida, Tadashi
Format: Article
Language:English
Subjects:
Antigens
Asthma
Biomarkers
Blood
Case reports
Case Series
Dermatitis
dupilumab
Ear diseases
eosinophilic chronic rhinosinusitis
eosinophilic pneumonia
Inflammatory diseases
Lavage
Neutrophils
Patients
Pneumonia
Radiography
Steroids
Tomography
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Several reports have described dupilumab‐induced eosinophilic pneumonia (EP) after treatment with dupilumab in patients with type 2 inflammatory disease. Other reports have suggested the efficacy of dupilumab for chronic EP (CEP). Whether dupilumab can be continued in patients with type 2 inflammatory disease who develop EP during dupilumab treatment remains unclear. We present herein three cases with different clinical presentations involving dupilumab and EP. In Case 1, dupilumab was discontinued because of dupilumab‐induced EP during the treatment of asthma. In Case 2, although pre‐existing idiopathic EP worsened during the treatment of eosinophilic chronic rhinosinusitis (ECRS), dupilumab was continued. In Case 3, CEP and ECRS were successfully treated with dupilumab and corticosteroids were discontinued. In conclusion, treatment with dupilumab in patients with type 2 inflammatory disease and idiopathic EP is worth considering if the benefits are deemed to outweigh the risks and careful attention is given to the clinical course. Several reports have described dupilumab‐induced eosinophilic pneumonia (EP) after treatment with dupilumab in patients with type 2 inflammatory disease. Other reports have suggested the efficacy of dupilumab for chronic EP (CEP). Whether dupilumab can be continued in patients with type 2 inflammatory disease who develop EP during dupilumab treatment remains unclear. We present herein three cases with different clinical presentations involving dupilumab and EP.
ISSN:2051-3380
2051-3380
DOI:10.1002/rcr2.1412